Tuesday, January 31, 2023

First COVID-19 shot for young kids could get U.S. FDA authorization on Friday


© Reuters. FILE PHOTO: FILE PHOTO: A woman holds a small bottle labelled with a “Coronavirus COVID-19 Vaccine” sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File Photo

(Reuters) -The U.S. drug regulator is expected to authorize the Pfizer Inc (NYSE:) and BioNTech SE (NASDAQ:) coronavirus vaccine for children aged 5 to 11 years on Friday, the New York Times reported https://www.nytimes.com/2021/10/29/us/politics/covid-vaccine-children.html, citing people familiar with the agency’s planning.

The U.S. Food and Drug Administration’s decision will make it the first COVID-19 shot for young children in the United States.

The FDA did not immediately respond to Reuters request for comment.

The decision is expected to make the vaccine available to 28 million American children – many of whom are back in school for in-person learning – in the coming days. It comes after a panel of advisers to the FDA voted overwhelmingly https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-advisers-weigh-pfizerbiontech-covid-19-vaccine-children-2021-10-26 to recommend the authorization on Tuesday.

An advisory panel to the U.S. Centers for Disease Control and Prevention (CDC) is scheduled to meet next week to consider recommendations on how the vaccine should be used in that age group. The CDC director will have the final say.

Only a few other countries, including China, Cuba and the United Arab Emirates, have so far cleared COVID-19 vaccines for children in this age group and younger.

Pfizer and BioNTech said their vaccine showed 90.7% efficacy against the coronavirus in a clinical trial of children aged 5 to 11.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link


Please enter your comment!
Please enter your name here



Related Stories